Analysts Set Expectations for Compass Therapeutics, Inc.’s Q1 2023 Earnings (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) – Analysts at HC Wainwright issued their Q1 2023 earnings estimates for Compass Therapeutics in a research note issued to investors on Wednesday, March 15th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.11) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q2 2023 earnings at ($0.12) EPS and Q3 2023 earnings at ($0.13) EPS.

A number of other research analysts have also weighed in on CMPX. Jefferies Financial Group started coverage on Compass Therapeutics in a report on Tuesday, January 31st. They set a “buy” rating and a $8.00 target price on the stock. Stifel Nicolaus initiated coverage on Compass Therapeutics in a research report on Thursday, January 26th. They set a “buy” rating and a $9.00 price objective for the company. Finally, EF Hutton Acquisition Co. I initiated coverage on Compass Therapeutics in a report on Friday, December 16th. They set a “buy” rating and a $10.30 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $9.05.

Compass Therapeutics Price Performance

CMPX stock opened at $3.40 on Friday. The stock has a market capitalization of $429.05 million, a P/E ratio of -8.10 and a beta of 0.93. Compass Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $5.65. The business has a 50-day moving average of $4.00 and a 200-day moving average of $3.84.

Insider Buying and Selling

In related news, CEO Thomas J. Schuetz purchased 10,000 shares of the firm’s stock in a transaction dated Friday, March 10th. The stock was bought at an average price of $3.37 per share, for a total transaction of $33,700.00. Following the purchase, the chief executive officer now directly owns 6,021,873 shares in the company, valued at approximately $20,293,712.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Thomas J. Schuetz purchased 10,000 shares of the firm’s stock in a transaction dated Friday, March 10th. The shares were purchased at an average cost of $3.37 per share, for a total transaction of $33,700.00. Following the completion of the transaction, the chief executive officer now directly owns 6,021,873 shares in the company, valued at approximately $20,293,712.01. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas J. Schuetz bought 20,000 shares of the stock in a transaction on Tuesday, January 31st. The stock was purchased at an average price of $4.05 per share, for a total transaction of $81,000.00. Following the completion of the purchase, the chief executive officer now directly owns 5,471,873 shares in the company, valued at $22,161,085.65. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 90,000 shares of company stock worth $355,300. 29.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently made changes to their positions in the company. UBS Group AG raised its holdings in Compass Therapeutics by 63.5% in the fourth quarter. UBS Group AG now owns 11,819 shares of the company’s stock worth $59,000 after buying an additional 4,591 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Compass Therapeutics during the 3rd quarter valued at about $33,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at $75,000. Boothbay Fund Management LLC purchased a new position in shares of Compass Therapeutics during the 4th quarter valued at $86,000. Finally, Barclays PLC raised its stake in Compass Therapeutics by 4,773.0% during the 4th quarter. Barclays PLC now owns 18,225 shares of the company’s stock valued at $91,000 after purchasing an additional 17,851 shares during the period. 54.27% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.